Itacitinib + Tocilizumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Steroid Refractory GVHD
Conditions
Steroid Refractory GVHD, Graft Vs Host Disease
Trial Timeline
Jan 20, 2020 → Dec 13, 2021
NCT ID
NCT04070781About Itacitinib + Tocilizumab
Itacitinib + Tocilizumab is a phase 1 stage product being developed by Incyte for Steroid Refractory GVHD. The current trial status is terminated. This product is registered under clinical trial identifier NCT04070781. Target conditions include Steroid Refractory GVHD, Graft Vs Host Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04070781 | Phase 1 | Terminated |
Competing Products
8 competing products in Steroid Refractory GVHD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Budesonide Nasal | Johnson & Johnson | Approved | 85 |
| Dapagliflozin + Sliding scale insulin | AstraZeneca | Approved | 85 |
| Ruxolitinib | Novartis | Approved | 85 |
| Omalizumab (Xolair) + Placebo | Novartis | Phase 2/3 | 65 |
| Ruxolitinib (RUX) + Best Available Therapy (BAT) | Novartis | Phase 3 | 77 |
| Rituximab | Roche | Phase 2 | 52 |
| Denosumab + Placebo for risendronate + Risendronate + Placebo for denosumab | Amgen | Phase 3 | 76 |
| Levetiracetam, Keppra | UCB | Approved | 82 |